Medidata Solutions Inc (NASDAQ:MDSO) – Research analysts at Dougherty & Co cut their FY2018 earnings per share (EPS) estimates for shares of Medidata Solutions in a research report issued on Monday. Dougherty & Co analyst G. Mannheimer now forecasts that the company will post earnings of $0.92 per share for the year, down from their previous forecast of $0.94. Dougherty & Co currently has a “Buy” rating and a $75.00 target price on the stock.
Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.10. The firm had revenue of $141.20 million during the quarter, compared to analyst estimates of $140.65 million. Medidata Solutions had a return on equity of 11.59% and a net margin of 8.14%. The business’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.33 earnings per share.
Shares of Medidata Solutions (NASDAQ:MDSO) remained flat at $$62.48 during trading on Wednesday. 806,300 shares of the stock traded hands, compared to its average volume of 635,074. The stock has a market cap of $3,661.76, a PE ratio of 71.82, a price-to-earnings-growth ratio of 3.07 and a beta of 1.58. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.50 and a quick ratio of 3.37. Medidata Solutions has a 52-week low of $54.36 and a 52-week high of $85.92.
Institutional investors have recently bought and sold shares of the company. Fortaleza Asset Management Inc. bought a new stake in shares of Medidata Solutions during the third quarter valued at approximately $155,000. Polen Capital Management LLC bought a new stake in shares of Medidata Solutions during the third quarter valued at approximately $205,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Medidata Solutions by 48.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,242 shares of the company’s stock valued at $205,000 after acquiring an additional 1,056 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Medidata Solutions during the second quarter valued at approximately $227,000. Finally, Hanseatic Management Services Inc. raised its stake in shares of Medidata Solutions by 14,915.0% during the third quarter. Hanseatic Management Services Inc. now owns 3,003 shares of the company’s stock valued at $234,000 after acquiring an additional 2,983 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.
In other Medidata Solutions news, EVP Michael Pray sold 5,944 shares of the firm’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $70.47, for a total value of $418,873.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Rouven Bergmann sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $65.40, for a total transaction of $130,800.00. Following the completion of the sale, the chief financial officer now directly owns 91,775 shares of the company’s stock, valued at approximately $6,002,085. The disclosure for this sale can be found here. In the last three months, insiders sold 24,010 shares of company stock valued at $1,630,556. 5.80% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/dougherty-co-analysts-decrease-earnings-estimates-for-medidata-solutions-inc-mdso.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.